Investors will focus on
Onconova Therapeutics, Inc.’s ( ONTX Quick Quote ONTX - Free Report) lead candidate, rigosertib, which is a proprietary phase III small molecule, when it reports fourth-quarter 2019 results.
The company’s performance over the previous four quarters has been mixed. It beat earnings estimates in three, while missed in one of the trailing four quarters, with the average positive surprise being 11.48%. In the last reported quarter, Onconova delivered a positive surprise of 1.32%.
Shares of the company have plunged 88.2% in the past year compared with the
industry’s 14.8% decline.
Let’s see how things have shaped up for the upcoming announcement.
Key Q4 Developments
Onconova is focused on discovering and developing novel small-molecule product candidates primarily to treat cancer. The company does not have any marketed product in its portfolio yet. Hence, we expect it to provide updates on rigosertib that inhibits cellular signaling in cancer cells by targeting RAS effector pathways, during the earnings call.
Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical studies assessing single-agent IV rigosertib in second-line higher-risk myelodysplastic syndrome (HR-MDS) patients (pivotal phase III INSPIRE study) and oral rigosertib plus azacitidine in first-line and refractory HR- MDS patients (phase II).
The company expects to complete the INSPIRE study in the first half of 2020 based on approaching 90% or 324 randomized patients of the required 360 randomized patients and the number of confirmed death events. We expect the company to provide updates on the enrollment status of the study during the conference call.
In December 2019, the company presented preliminary genomics data from the INSPIRE study. Moreover, updated data from the phase II study of oral rigosertib + azacitidine (AZA) Versus Single Agent AZA in Treatment-Naive Patients with HR-MDS was presented in an oral presentation. At study entry, 50 different mutations were identified at baseline prior to patients receiving study treatment with either IV rigosertib or physician’s choice (PC).
What Our Model Indicates
Our proven model does not conclusively predict an earnings beat for Onconova this time around. The combination of a positive
Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here, as you will see below. Earnings ESP: Onconova has an Earnings ESP of 0.00%, as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at a loss of 5 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #2. You can see . the complete list of today’s Zacks #1 Rank stocks here
Stocks That Warrant a Look
Here are a few healthcare stocks worth considering, as our model shows that these have the right mix of elements to beat estimates in the to-be-reported quarter.
AVEO Pharmaceuticals Inc.
AVEO has an Earnings ESP of +28.04% and a Zacks Rank #3.
ChemoCentryx, Inc. (
CCXI Quick Quote CCXI - Free Report) has an Earnings ESP of +14.18% and a Zacks Rank #3.
Harpoon Therapeutics Inc.
HARP has an Earnings ESP of +13.51% and a Zacks Rank #3. Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>